Duchenne Muscular Dystrophy Gene Therapy
- 1 February 2024
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 24 (1) , 17-28
Abstract
S: Duchenne and Becker muscular dystrophies are allelic X-linked recessive neuromuscular diseases affecting both skeletal and cardiac muscles. Therefore, owing to their single X chromosome, the affected boys receive pathogenic gene mutations from their unknowing carrier mothers. Current pharmacological drugs are palliative that address the symptoms of the disease rather than the genetic cause imbedded in the Dystrophin gene DNA sequence. Therefore, alternative therapies like gene drugs that could address the genetic cause of the disease at its root are crucial, which include gene transfer/implantation, exon skipping, and gene editing. Presently, it is possible through genetic reprogramming to engineer AAV vectors to deliver certain therapeutic cargos specifically to muscle or other organs regardless of their serotype. Similarly, it is possible to direct the biogenesis of exosomes to carry gene editing constituents or certain therapeutic cargos to specific tissue or cell type like brain and muscle. While autologous exosomes are immunologically inert, it is possible to camouflage AAV capsids, and lipid nanoparticles to evade the immune system recognition. In this review, we highlight current opportunities for Duchenne muscular dystrophy gene therapy, which has been known thus far as an incurable genetic disease. This article is a part of Gene Therapy of Rare Genetic Diseases thematic issue.Keywords
This publication has 120 references indexed in Scilit:
- Melanocytes—A novel tool to study mitochondrial dysfunction in Duchenne muscular dystrophyJournal of Cellular Physiology, 2012
- Restoration of the Dystrophin-associated Glycoprotein Complex After Exon Skipping Therapy in Duchenne Muscular DystrophyMolecular Therapy, 2012
- Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular DystrophyMolecular Therapy Nucleic Acids, 2012
- Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trialsBrain, 2011
- Debio-025 is more effective than prednisone in reducing muscular pathology in mdx miceNeuromuscular Disorders, 2010
- Exon Skipping and Duchenne Muscular Dystrophy Therapy: Selection of the Most Active U1 snRNA Antisense Able to Induce Dystrophin Exon 51 SkippingMolecular Therapy, 2010
- Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohortHuman Mutation, 2009
- Inhibition of myostatin with emphasis on follistatin as a therapy for muscle diseaseMuscle & Nerve, 2009
- Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophyNature Medicine, 2008
- Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporinsProceedings of the National Academy of Sciences, 2007